GLUE vs. MTZ

Last updated Jun 3, 2026

GLUE (Monte Rosa Therapeutics, Inc.) and MTZ (MasTec, Inc.) are both stocks. GLUE operates in Biotechnology (Healthcare), while MTZ operates in Engineering & Construction (Industrials). Over the past 3 years, GLUE returned 32.89%/yr vs 51.36%/yr for MTZ. At a 0.23 correlation, their price movements are largely independent.

Performance

GLUE vs. MTZ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monte Rosa Therapeutics, Inc. (GLUE) and MasTec, Inc. (MTZ). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GLUE achieves a 13.14% return, which is significantly lower than MTZ's 68.51% return.

GLUE

• 1D: -9.81%
• 1M: -5.64%
• YTD: 13.14%
• 6M: 15.12%
• 1Y: 294.22%
• 3Y*: 32.89%
• 5Y*: —
• 10Y*: —

MTZ

• 1D: 1.16%
• 1M: -12.24%
• YTD: 68.51%
• 6M: 71.99%
• 1Y: 134.27%
• 3Y*: 51.36%
• 5Y*: 25.15%
• 10Y*: 32.02%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GLUE vs. MTZ - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GLUE Monte Rosa Therapeutics, Inc.	13.14%	125.94%	22.83%	-25.76%	-62.73%	-3.59%
MTZ MasTec, Inc.	68.51%	59.67%	79.79%	-11.26%	-7.53%	-13.80%

Correlation

The correlation between GLUE and MTZ is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.24
Correlation (All Time) Calculated using the full available price history since Jun 25, 2021	0.23

Fundamentals

EPS GLUE : -$2.26 MTZ : $5.71
PS Ratio GLUE : 23.76 MTZ : 1.89
Total Revenue (TTM) GLUE : $42.95M MTZ : $15.28B
Gross Profit (TTM) GLUE : $34.56M MTZ : $1.85B
EBITDA (TTM) GLUE : -$139.25M MTZ : $1.10B

Return for Risk

GLUE vs. MTZ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GLUE

GLUE Risk / Return Rank: 94
GLUE Sharpe Ratio Rank: 95
GLUE Sortino Ratio Rank: 96
GLUE Omega Ratio Rank: 92
GLUE Calmar Ratio Rank: 95
GLUE Martin Ratio Rank: 94

MTZ

MTZ Risk / Return Rank: 95
MTZ Sharpe Ratio Rank: 96
MTZ Sortino Ratio Rank: 93
MTZ Omega Ratio Rank: 93
MTZ Calmar Ratio Rank: 96
MTZ Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GLUE vs. MTZ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monte Rosa Therapeutics, Inc. (GLUE) and MasTec, Inc. (MTZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GLUE	MTZ	Difference
Sharpe ratio Return per unit of total volatility	3.20	3.52	-0.32
Sortino ratio Return per unit of downside risk	4.33	3.65	+0.68
Omega ratio Gain probability vs. loss probability	1.50	1.51	-0.01
Calmar ratio Return relative to maximum drawdown	7.75	7.83	-0.07
Martin ratio Return relative to average drawdown	17.17	26.11	-8.94
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GLUE vs. MTZ - Sharpe Ratio Comparison

The current GLUE Sharpe Ratio is 3.20, which is comparable to the MTZ Sharpe Ratio of 3.52. The chart below compares the historical Sharpe Ratios of GLUE and MTZ, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GLUE	MTZ	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.20	3.52	-0.32
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.59	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.73	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.03	0.20	-0.23

Drawdowns

GLUE vs. MTZ - Drawdown Comparison

The maximum GLUE drawdown since its inception was -94.08%, roughly equal to the maximum MTZ drawdown of -97.72%. Use the drawdown chart below to compare losses from any high point for GLUE and MTZ.

Drawdown Indicators

	GLUE	MTZ	Difference
Max Drawdown Largest peak-to-trough decline	-94.08%	-97.72%	+3.64%
Max Drawdown (1Y) Largest decline over 1 year	-41.84%	-17.24%	-24.60%
Max Drawdown (3Y) Largest decline over 3 years	-67.19%	-61.01%	-6.18%
Max Drawdown (5Y) Largest decline over 5 years	—	-61.01%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-67.92%	—
Current Drawdown Current decline from peak	-57.97%	-16.28%	-41.69%
Average Drawdown Average peak-to-trough decline	-74.62%	-51.91%	-22.71%
Ulcer Index Depth and duration of drawdowns from previous peaks	18.89%	5.17%	+13.72%

Volatility

GLUE vs. MTZ - Volatility Comparison

Monte Rosa Therapeutics, Inc. (GLUE) has a higher volatility of 17.10% compared to MasTec, Inc. (MTZ) at 12.49%. This indicates that GLUE's price experiences larger fluctuations and is considered to be riskier than MTZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GLUE	MTZ	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.10%	12.49%	+4.61%
Volatility (6M) Calculated over the trailing 6-month period	57.34%	29.12%	+28.22%
Volatility (1Y) Calculated over the trailing 1-year period	92.88%	38.38%	+54.50%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	101.35%	42.56%	+58.79%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	101.35%	43.75%	+57.60%

Dividends

GLUE vs. MTZ - Dividend Comparison

Neither GLUE nor MTZ has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both GLUE and MTZ in my portfolio?

GLUE and MTZ have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GLUE or MTZ?

GLUE has higher volatility (17.10%) compared to MTZ (12.49%). In terms of maximum drawdown, GLUE dropped -94.08% vs MTZ's -97.72%.

Which has better risk-adjusted returns?

MTZ currently has the higher Sharpe Ratio (3.52 vs 3.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.